Pediatric spinal oligodendrogliomas are rare and aggressive tumors. They do not share the same molecular features of adult oligodendroglioma, and no previous reports have examined the molecular features of pediatric spinal oligodendroglioma. We present the case of a child with a recurrent spinal anaplastic oligodendroglioma. We performed whole exome (paired tumor and germline DNA) and transcriptome (tumor RNA) sequencing, which revealed somatic mutations in NF1 and FGFR1. These data allowed us to explore potential personalized therapies for this patient and expose molecular drivers that may be involved in similar cases.
INTRODUCTION
Spinal cord oligodendrogliomas are very rare tumors, comprising <5% of spinal cord tumors in all ages. [1] [2] [3] [4] [5] In children, spinal tumors are even less common, with spinal gliomas accounting for only 1-3.5% of all pediatric central nervous system (CNS) tumors; only a few cases and one case series of two spinal oligodendrogliomas have been reported in the pediatric population. 3, 5, 6 While standard treatment consists of Abbreviations: AO, anaplastic oligodendroglioma; ATRX, alpha thalassemia/mental retardation syndrome X-linked; CNS, central nervous system; FGFR, fibroblast growth factor receptor; HGG, high-grade glioma; IDH, isocitrate dehydrogenase; MAPK, mitogen-activated protein kinase; MEK, MAPK/ERK kinase; MGMT, O-6-methylguanine-DNA methyltransferase; MRI, magnetic resonance imaging; NF1, neurofibromatosis type I surgical resection, alkylating chemotherapy, and radiation therapy, there is no consistently followed regimen given the rarity of pediatric high-grade spinal oligodendrogliomas.
The field of neuro-oncology is increasingly moving toward personalized treatment options for patients. The molecular analysis of adult gliomas by numerous investigators has resulted in the identification of several cytogenetic markers that confer varying prognostic benefits and therapeutic responses. 1, 7 However, these features (e.g., 1p/19q codeletion) are less informative in the pediatric glioma setting. 8 Furthermore, the molecular features of pediatric spinal oligodendroglioma specifically have not previously been examined. We present a case of a child with a spinal anaplastic oligodendroglioma (AO) and discuss our investigation of potential targeted agents using tumor sequencing data. 
RESULTS
A 3-year-old female child presented with a 2-month history of neck pain, left leg weakness, asymmetric gait, and right head tilt. Spinal magnetic resonance imaging (MRI) revealed a 6 × 1 cm enhancing intramedullary mass extending from C4 to T4. She underwent uncomplicated subtotal resection of the primary tumor (Fig. 1A) . At the time of recurrence, the patient was enrolled on PEDS-MIONCOSEQ, a precision oncology study involving whole exome (paired tumor and germline DNA) and transcriptome (tumor RNA) sequencing. Clinically integrated sequencing was performed according to previous published methodology. 9 Nucleic acid preparation, highthroughput sequencing, and computational analysis were performed using standard protocols in our sequencing laboratory in the Michigan Center for Translational Pathology, which adheres to the Clinical Laboratory Improvement Amendments.
Sequencing revealed a somatic point mutation and three small deletions in NF1, consistent with biallelic inactivation (Supplementary Table S1 ). There was no evidence of germline NF1 alterations, skin lesions, or family history suggestive of neurofibromatosis type I (NF1).
Sequencing also revealed two somatic activating missense mutations in FGFR1 (Supplementary Table S2 ). No mutations in BRAF were observed, which are recurrently found in some oligodendrogliomas. 10 Sequencing results were otherwise unremarkable ( Supplementary Fig.   S1 ). Results of her tumor sequencing were discussed in our multidisciplinary CNS precision medicine tumor board -teleconferenced with clinicians at multiple children's hospitals -which recommended adjuvant therapy with a fibroblast growth factor receptor (FGFR) inhibitor and/or a MAPK/ERK kinase (MEK) (where ERK is extracellular signalregulated kinases) inhibitor, although she was not eligible for any clinical trials using these agents at that time. Therapy with the FGFR inhibitor ponatinib (off-study) is planned as a maintenance therapy upon clinical improvement.
DISCUSSION
The prognosis for pediatric high-grade gliomas (HGGs) remains dismal despite multimodal treatment approaches, and the few reports on outcomes for spinal cord HGGs are also discouraging. 5, 11, 12 High-grade oligodendrogliomas in any location are uncommon in children and have unfavorable outcomes as well. 4, 11, 12 Only four AOs were confirmed among 250 HGG patients treated on the CCG-945 Children's Cancer Study Group clinical trial, and four patients with non-glioblastoma, non-anaplastic astrocytoma tumors among 107 patients with HGG treated on the ACNS0126 Children's Oncology Group trial. 11, 12 Lundar et al. followed 35 children with cerebral oligodendrogliomas and found 5-and 10-year overall survival of only 27% and 18%, respectively, for the anaplastic tumors. 4 The prognosis of the very few reported pediatric spinal AO is also poor; Merchant et al. reported two patients with AO among 11 high-grade pediatric spinal tumor patients who survived only 29 and 39 months, respectively. 5 The molecular features of adult oligodendroglioma are well described. 1p/19q codeletion is found in 50-70% of adult gliomas and confers an improved response to chemotherapy and overall survival. 1, 7 However, this high frequency and survival benefit for codeletion have not been shown in pediatric gliomas. 4, 8, 12, 13 Similarly, methylation of the MGMT promoter and IDH1 mutations are only rarely seen in pediatric HGG. 14 FGFR1 interfaces with several pathway. 19 Sporadic FGFR1 mutations have been observed in many tumor histologies, including two medulloblastoma, one low-grade glioma, and three glioblastoma cases. 17 Given the lack of known effective therapies for the recurrent spinal AO in this child and the molecular leads to the oncogenesis of her tumor from the sequencing, targeted therapies are a consideration. In particular, inhibition of the Ras-MAPK pathway could be accomplished at the sites of both observed somatic mutations (Fig. 2) . This could be done upstream via FGFR1 inhibition (e.g., ponatinib) or downstream via MEK inhibition (e.g., trametinib, which is actively being studied in other NF1-deficient tumors). 20 Given that 64% of the sequenced tumor fraction expressed an FGFR1 mutation and only 20% expressed alterations in NF1, we will initiate ponatinib for this patient. Ponatinib displays moderate CNS penetration and has published use in the pediatric population. 21 Future combination therapy with trametinib will be considered if the patient tolerates ponatinib therapy and does not display objective response. 
